Edited by: Bodo Niggemann
Probiotics in primary prevention of allergic disease – follow-up at 8–9 years of age
Article first published online: 30 JUL 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 68, Issue 8, pages 1015–1020, August 2013
How to Cite
Probiotics in primary prevention of allergic disease – follow-up at 8–9 years of age. Allergy 2013; 68: 1015–1020., , .
- Issue published online: 23 AUG 2013
- Article first published online: 30 JUL 2013
- Manuscript Accepted: 25 APR 2013
- Arla Foods AB. Grant Number: 222720
- Swedish Society for Medical research
- Swedish Asthma and Allergy Association
- the Ekhaga and Oskar foundations
- allergy prevention;
- Lactobacillus paracasei ssp paracasei F19;
- nitric oxide
Long-term effects of probiotics in primary prevention of allergic disease need further evaluation. We previously reported a reduced cumulative incidence of infant eczema by feeding Lactobacillus paracasei ssp paracasei F19 (LF19) during weaning. Therefore, we assessed effects of LF19 on the prevalence of allergic disease at school age.
In a double-blind placebo-controlled trial infants were randomized to daily intake of cereals with (n = 89) or without LF19 108 CFU (n = 90) from 4–13 months of age. At age 8–9, we evaluated the prevalence of allergic disease (eczema, allergic rhinitis, asthma, and food allergy) by clinical examination and validated questionnaires. IgE sensitization was assessed by skin prick test (inhalant allergens) and specific IgE levels (food allergens). Lung function was evaluated by a spirometry reversibility test. Fractional exhaled nitric oxide (FENO) was measured.
Of 171 children that completed the intervention, 121 were assessed at age 8–9. In the probiotic group, 15/59 (25%) were diagnosed with any allergic disease vs 22/62 (35%) in the placebo group [OR (95% CI) 0.62 (0.28–1.36)]. Corresponding numbers for IgE-associated allergic disease were 9/53 (17%) vs 12/59 (20%) [0.80 (0.31–2.09)]. Median (25th-75th percentile) FENO was 9 (8–12) in the probiotic vs 8 (7–12) ppb in the placebo group (P > 0.05). There was no effect of LF19 on lung function measures (P > 0.05).
There was no long-term effect of LF19 on any diagnosed allergic disease, airway inflammation or IgE sensitization. This suggests delayed eczema onset but to fully examine long-term benefits a larger study population had been needed.